Edition:
United States

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Global Select Market

2.31USD
2 Dec 2016
Change (% chg)

-- (+0.00%)
Prev Close
$2.31
Open
$2.29
Day's High
$2.31
Day's Low
$2.29
Volume
11,117
Avg. Vol
--
52-wk High
--
52-wk Low
--

Select another date:

Thu, Nov 3 2016

BRIEF-Vical reports Q3 loss per share $0.24

* Vical Inc says projecting net cash burn for 2016 between $8 million and $11 million

BRIEF-Vical initiates phase 2 trial of HSV-2 therapeutic DNA vaccine

* Vical announces initiation of a phase 2 trial of its HSV 2 therapeutic DNA vaccine for genital herpes

Astellas, Vical herpes vaccine fails mid-stage study

Japan's Astellas Pharma Inc and San Diego-based Vical Inc said their experimental herpes vaccine failed a mid-stage study involving certain kidney transplant patients.

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

* Results from study demonstrated that trial did not meet its primary endpoint

BRIEF-Anges MG to work together with Vical Incorporated on DNA vaccine business

* Says the company and Vical Incorporated has agreed to work together on DNA vaccine business, which includes research, development and manufacturing

BRIEF-Vical Q2 loss per share $0.14

* Projecting net cash burn for 2016 between $8 million and $11 million Source text for Eikon: Further company coverage:

BRIEF-Vical announces $7.8 mln equity investment by partner Anges MG

* Vical announces $7.8 million equity investment by partner, Anges MG

BRIEF-AnGes MG to invest Vical and to hold 18.6 pct stake in it

* Says it to buy 1,841,420 shares of Vical Inc for $4.2448 per share on Aug. 3

BRIEF-Vical's phase 1/2 trial data shows bivalent vaccine imparts reduction in genital herpes lesions durable to 9 months

* Initial top line 3-month data announced in june 2015 showed neither monovalent nor bivalent vaccine met primary endpoint of viral shedding rate reduction from baseline

Select another date: